



Contents lists available at [ScienceDirect](http://www.sciencedirect.com)

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Erratum

Erratum to “2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles—O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase)” [Bioorg. Med. Chem. Lett. 18 (2008) 6171]

Joseph S. Warmus^{a,*}, Cathlin Flamme^a, Lu Yan Zhang^a, Stephen Barrett^a, Alexander Bridges^a, Huifen Chen^c, Richard Gowan^b, Michael Kaufman^a, Judy Sebolt-Leopold^b, Wilbur Leopold^b, Ronald Merriman^b, Jeffrey Ohren^c, Alexander Pavlovsky^c, Sally Przybranowski^b, Haile Tecle^a, Heather Valik^b, Christopher Whitehead^c, Erli Zhang^c

^a Department of Chemistry, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA

^b Department of Oncology Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA

^c Discovery Technologies Structural and Analytical Sciences, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA

The publisher regrets that the IC50s in all the tables are listed as M, not μ M.

DOI of original article: [10.1016/j.bmcl.2008.10.015](https://doi.org/10.1016/j.bmcl.2008.10.015).

* Corresponding author at present address: Pfizer Global Research and Development, CVMED Chemistry, Eastern Point Road, Groton, CT 06340, USA. Tel.: +1 860 686 9354; fax: +1 860 686 0001.

E-mail address: Joseph.Warmus@Pfizer.com (J.S. Warmus).